Literature DB >> 17425506

Colorectal cancer: a multipathway disease.

Jeremy R Jass1.   

Abstract

The linear sequence of genetic alterations illustrated in the Vogelstein model provides a readily understandable illustration of the fundamental principles underlying colorectal tumorigenesis. However, it is now clear that colorectal cancer is a multi-pathway disease. In this review, the concept that inactivation of the tumor suppressor gene APC serves to initiate virtually all colorectal cancers is shown to be an oversimplification. APC inactivation may have important tumorigenic pathogenic effects beyond the mere initiation of precancerous adenomas. Furthermore, the early evolution of colorectal neoplasia must sometimes occur by mechanisms other than inactivation of APC or related alterations that would drive dysregulated Wnt pathway signaling. Oncogenic mutations implicating both BRAF and KRAS are highlighted as alternative initiating steps that synergize with DNA methylation and occur within the context of serrated polyps. CRC comprises subgroups with particular clinical, pathological, and molecular features.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17425506     DOI: 10.1615/critrevoncog.v12.i3-4.50

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  53 in total

Review 1.  DNA Methylation Dynamics During Differentiation, Proliferation, and Tumorigenesis in the Intestinal Tract.

Authors:  Can-Ze Huang; Tao Yu; Qi-Kui Chen
Journal:  Stem Cells Dev       Date:  2015-10-20       Impact factor: 3.272

2.  Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.

Authors:  Mehrdad Zeinalian; Mohammad Hassan Emami; Rasoul Salehi; Azar Naimi; Mohammad Kazemi; Morteza Hashemzadeh-Chaleshtori
Journal:  J Gastrointest Cancer       Date:  2015-06

Review 3.  The role of viral and bacterial pathogens in gastrointestinal cancer.

Authors:  Michael Selgrad; Peter Malfertheiner; Lucia Fini; Ajay Goel; C Richard Boland; Luigi Ricciardiello
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

4.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

Review 5.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

6.  Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy.

Authors:  S Gattenlöhner; B Etschmann; V Kunzmann; A Thalheimer; M Hack; G Kleber; H Einsele; C Germer; H-K Müller-Hermelink
Journal:  J Oncol       Date:  2010-03-10       Impact factor: 4.375

7.  Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study.

Authors:  Adam Naguib; Panagiota N Mitrou; Laura J Gay; James C Cooke; Robert N Luben; Richard Y Ball; Alison McTaggart; Mark J Arends; Sheila A Rodwell
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

8.  CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese.

Authors:  Peng Qi; Can-ping Ruan; Hao Wang; Fei-guo Zhou; Xin-yun Xu; Xing Gu; Yun-peng Zhao; Tong-hai Dou; Chun-fang Gao
Journal:  Int J Colorectal Dis       Date:  2009-09-29       Impact factor: 2.571

9.  Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Authors:  W Chua; D Goldstein; C K Lee; H Dhillon; M Michael; P Mitchell; S J Clarke; B Iacopetta
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

10.  KRAS and TP53 mutations in colorectal carcinoma.

Authors:  Khawla S Al-Kuraya
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.